SHSam Halabi

Sam Halabi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sam Halabi has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Aligning Licensure and Recommended Use to Expedite Vaccine Access in Response to the Ongoing Bundibugyo Ebolavirus Epidemic in Central Africa

    by George L. O’Hara, Sam Halabi

    The ongoing Orthoebolavirus bundibugyoense—Bundibugyo virus (BDBV)—epidemic is the worst Ebolavirus outbreak in a decade and is rapidly expanding, with >4600 suspected cases in the Democratic Republic of Congo (DRC) alone. It has caused 2186 deaths and spread to neighboring countries. As BDBV has no approved vaccine, timely response will require adapted use of existing vaccines approved for other ebolaviruses and expedited development of novel vaccines targeted toward BDBV. Access to vaccines is fundamental to public health emergency response and generally depends on two expert bodies in each country: a national regulatory authority (e.g., the US Food and Drug Administration (FDA)) and a national immunization advisor. Receding traditional global health assistance compounds already-limited licensure and recommended use in the DRC and other low-income countries confronting recent outbreaks of Ebola, Marburg, and mpox, exacerbating access gaps for high-risk populations. This commentary thus clarifies the critical importance of a robust national immunization advisor, coordinated closely with expanded licensure, in expediting access to vaccines and other essential epidemic response tools. Using the regulatory responses of the Republic of Rwanda and DRC, it demonstrates that clearer delineation of roles between these bodies is critical for effective response, can help prioritize self-sufficiency and greater regional public health cooperation, and will thus enable swifter control of Bundibugyo.

  • Open Access

    Community needs for FAIR pathogen data: a cross-sectional survey of infectious-disease researchers and educators

    by Geert van Geest, Daniel Thomas-Lopez, Anna A. Feitzinger, Lily A. Weissgold, Sam Halabi, Isabel Cuesta, Erik Hjerde, Kim Tamara Gurwitz, Nishtha Arora, Aitana Neves, et al.

    Background: Datasets related to infectious diseases are essential for public health decision-making, yet their reuse remains limited by persistent barriers to data sharing and integration. Achieving data that are Findable, Accessible, Interoperable, and Reusable (FAIR) is widely recognized as essential for accelerating scientific discovery and enabling coordinated responses to emerging threats, but the needs of the global pathogen data community have not been systematically characterized. Aim: This study, conducted by the Pathogen Data Network (PDN), aims to identify infrastructural and educational priorities among stakeholders working with infectious disease-related data—namely researchers, educators, healthcare professionals, bioinformaticians, and policymakers who generate, curate, or use pathogen data, in order to guide community-responsive support for data sharing and interoperability. Methods: A cross-sectional stakeholder survey was disseminated as an open, non-probability (convenience) survey to prospective participants reached through PDN networks, targeted mailing lists, and open professional and social-media channels. A total of 136 responses from researchers, healthcare professionals, bioinformaticians, and educators were analyzed descriptively to identify prioritized barriers, training needs, and preferred support mechanisms. Results: Respondents consistently identified structural constraints as the primary impediments to effective data use, including limited funding (74%), data-aggregation challenges (68%), and a shortage of skilled personnel (52%). Respondents identified bioinformatics for infectious disease research (68%) as the highest priority for training, followed by guidance on using the integrated pathogen data and tools portal provided by the PDN, the Pathogens Portal (51%). The Pathogens Portal was also ranked as the most essential PDN resource (72%). Preferred training formats included virtual short courses (68%) and webinars (66%). Notably, while researchers emphasized technical subjects like machine learning, educators prioritized foundational case studies. Conclusion: These findings provide an evidence-based descriptive summary of community needs and suggest that barriers to FAIR pathogen data are predominantly systemic rather than purely technological. The survey framework and openly available dataset offer a reusable template for assessing needs in other communities and regions. By aligning training, infrastructure development, and outreach with empirically identified priorities, organizations supporting infectious disease research can strengthen the interoperability and reuse of data and establish a benchmark for future community-driven improvements.

  • Open Access

    No fault vaccine injury compensation after COVID-19: A systematic literature review and proposed typology

    by Sam Halabi, Nishtha Arora, Alison Durran, Qianhan Qian, Shabna Ummer, Katherine Ginsbach, Kashish Aneja

    The COVID-19 pandemic brought about a unique and rapid period of global vaccine innovation. It revealed structural challenges not only in global vaccine affordability and distribution but in the liability and indemnity structures that can both impede access and affect fair outcomes for the small number of people who suffer severe side effects. This review examines vaccine injury and compensation mechanisms, including no-fault compensation schemes, aimed at addressing both the liability and indemnity concerns of developers and the compensation due those suffering severe side effects. The ultimate aim of the review is to provide a classification of systems for those countries that are considering adopting NFCS as part of their broader public health readiness and preparedness strategies.


  • Legal preparedness for One Health: evolving legal and institutional frameworks for improved global health security

    by Katherine Ginsbach, Stefania Negri, Kashish Aneja, Emanuele Cesta, Sandro Bonfigli, Sam Halabi

    Faced with major global health challenges including antimicrobial resistance, emerging infectious diseases, climate change, degradation of ecological systems, loss of biodiversity and food safety risks, the world is progressively moving towards embracing the One Health approach. The use of appropriate legal frameworks can translate One Health goals into reality and legal preparedness stands centre and forefront to ensure that law provides the necessary basis for One Health operationalisation. Indeed, to successfully implement the One Health approach it is important that appropriate legal frameworks are in place to govern structural changes; support the development of multisectoral infrastructures; establish linkages among relevant sectors and facilitate their coordination; regulate integrated processes and working methods. This paper examines the legal potential of a One Health approach for laws and policies to be applied to major global health challenges. It focuses on the relevance of One Health legal preparedness for better global health security and on the contribution provided by the Global Health Security Agenda (GHSA) Legal Preparedness Action Package through the work of its One Health Sub-working group.

  • Global Health Governance: The system we inherited and the need for an equitable decolonized global health governance system

    by Sarah L. Bosha, Alison Durran, Sam Halabi

    The article examines the historical development of global health from its genesis in colonial-era tropical medicine, to the creation of the World Health Organization – formed to advance health rights for all. The authors call for continued reforms to the global health governance system to mitigate the enduring impact of colonialism.


  • Open Access

    Global and national actions to prevent trade in substandard and adulterated medicines

    by Richard Wilder, Sam Halabi, Lawrence O. Gostin

    Recent mass-poisoning events caused by substandard medicines placed in global markets raise the question as to what more can be done to stop it. Efforts have been underway for years at the World Health Organization and other multilateral fora, such as the National Academies of Medicine in the U.S. While these efforts have led to improvements, several gaps remain which, unless addressed, will allow this problem in international trade to continue. Some countries have failed to implement the standards set by the WHO by not fully empowering national regulatory agencies to lead national efforts. Further, some countries do not fully exercise their responsibility under WHO standards to confirm that the information in documents accompanying internationally traded medicines is complete, accurate, and current. It is time to revisit international standards in this area to determine the causes of these problems and to address them.


  • Global Health Law for a Safer and Fairer World

    by Sam Halabi, Lawrence O. Gostin, Olohikhuae Egbokhare, Matthew M. Kavanagh


  • Open Access

    Equitable Vaccine Access in Light of COVID-19 Vaccine Procurement Strategies in Africa

    by George L. O’hara, Sam Halabi, Olohikhuae Egbokhare

    (1) Background: This study addresses two weaknesses in current international efforts to prevent and prepare for the next pandemic: the lack of robust evidence supporting global policy measures and the corresponding extent to which those measures advance equity. (2) Methods: Using UNICEF’s publicly available but underused COVID-19 Market Dashboard database, we conducted a cross-sectional analysis of vaccine deliveries as of mid-2022 and vaccine procurement strategies used by African low- and lower middle-income countries (LMICs) over the course of the COVID-19 pandemic. (3) Results: Pooled procurement of the kind typified by COVAX (a clearinghouse for high-income-country contributions of vaccines and financing toward the end of equitable LMIC procurement) crowded out alternative strategies that must be supported in future: regional procurement, donation, and bilateral procurement (binding agreement between two parties: one seller (i.e., a national government or a vaccine manufacturer) and one recipient (i.e., national government)), which showed a significant relationship with technology transfer and advancing local production capacity. (4) Conclusions: Expanding the scope of vaccine procurement alternatives to COVAX such as regional pooled procurement and bilateral procurement can stratify risk of supply agreements not materializing in actual supply. Sharing the technology necessary to produce vaccines with LMICs can mitigate obstacles to bilateral procurement. A pooled purchase alliance to procure vaccine doses on behalf of participating countries within a given region can benefit LMICs by accounting for infrastructure limitations that these countries share. Finally, donations bolster global redistributed supply essential to LMICs.